ArticleResearch square2024
Plasmodium SEY1 is a novel druggable target that contributes to imidazolopiperazine mechanism of action.
Elizabeth Winzeler, Krypton Carolino, Mariana Laureano De Souza, Daisy Chen, Jean-Claude Farre, James Blauwkamp, Sabrina Absalon, Sonja Ghidelli-Disse, Alexander Morano, Jeffrey Dvorin and 2 more
Abstract readPreprint
In one paragraphArticle in Research square, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
12 authors.
Krypton CarolinoUniversity of California, San Diego.
Mariana Laureano De SouzaUniversity of California, San Diego.
Jean-Claude FarreUniversity of California, San Diego.
James Blauwkamp
Sabrina Absalon
Sonja Ghidelli-Disse
Alexander Morano
Maria Jose Lafuente-Monasterio
Francisco-Javier Gamo
Funding
Training Program in Basic Clinical GeneticsT32GM008666 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI HAMILTON, BRUCE A · 1998 to 2021
$8.6MGRADUATE TRAINING PROGRAM IN BIONFORMATICST32GM008806 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BAFNA, VINEET, REN, BING · 2001 to 2020
$6.2MDiscovery of chemically validated malaria liver stage targetsR01AI090141 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI WINZELER, ELIZABETH A · 2011 to 2019
$3.4MMolecular mechanisms of schizogony in malaria parasitesR01AI145941 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI DVORIN, JEFFREY D · 2019 to 2023
$3.1MUC San Diego RAPID Faculty Development Program in Infectious DiseasesR25AI147376 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ADRIANA H TREMOULET, Joann Trejo · 2020 to 2026
$2.5MGraduate Training Program in BioinformaticsT32GM139790 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BAFNA, VINEET, GAASTERLAND, THERESA · 2021 to 2025
$2.1MCharacterizing a Serine-Threonine Phosphatase Essential for Asexual Replication in Plasmodium falciparumF31AI157041 · NIAID · HARVARD MEDICAL SCHOOL · PI MORANO, ALEXANDER AENEAS · 2022 to 2024
$91kNIAID NIH HHS F31 AI157041NIAID NIH HHS R01 AI090141NIAID NIH HHS R01 AI145941NIAID NIH HHS R25 AI147376NIGMS NIH HHS T32 GM008666NIGMS NIH HHS T32 GM008806NIGMS NIH HHS T32 GM139790
6 · The paper itselfAbstract
The precise mode of action of ganaplacide (KAF156), a phase III antimalarial candidate, remains elusive. Here we employ omics-based methods with the closely related chemical analog, GNF179, to search for potential
Identifiers
PMID39399671
PMCPMC11469372
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390